The role of surgical resection in Unicentric Castleman’s disease: a systematic review by Mitsos, Sofoklis et al.
PRACA ORYGINALNA
36
REVIEWS
www.journals.viamedica.pl
Address for correspondence: Sofoklis Mitsos MD, PhD, Department of Thoracic Surgery University College London Hospitals (UCLH) 16–18 Westmoreland St. W1G 8PH, 
London, UK, e-mail: sophocmit@yahoo.gr, tel. +44(0)7523198960
DOI: 10.5603/ARM.2018.0008
Received: 13.11.2017
Copyright © 2018 PTChP
ISSN 2451–4934
Sofoklis Mitsos1, Alexandros Stamatopoulos2, Davide Patrini1, Robert S. George1, David R. Lawrence1, 
Nikolaos Panagiotopoulos1
1Department of Thoracic Surgery, University College London Hospitals (UCLH), London, UK
2Academic Orthopedic Department, “Papageorgiou” General Hospital, Thessaloniki, Greece;CORE-Center for Orthopedic Research at 
CIRI-AUTh, Aristotle University Medical School, Thessaloniki, Greece
The role of surgical resection in Unicentric Castleman’s disease: 
a systematic review
The authors declare no financial disclosure
Abstract
Introduction: Castleman’s disease is a rare benign lymphoproliferative disorder of unknown etiology. The disease occurs in two 
clinical forms with different prognoses, treatments and symptoms: a unicentric form (UCD), which is solitary, localized, and a mul-
ticentric form characterized by generalized lymphadenopathy and systemic symptoms. This article aims to review the current 
literature to consolidate the evidence surrounding the curative potential of surgical treatment to the unicentric type.
Material and methods: A systematic review of English-language literature was performed and databases (Medline, Pubmed, 
the Cochrane Database and grey literature) were searched to identify articles pertaining to the treatment of unicentric form of 
Castleman’s disease. Each article was critiqued by two authors using a structured appraisal tool, and stratified according to the 
level of evidence.
Results: After application of inclusion criteria, 14 studies were included. There were no prospective randomized control studies 
identified. One meta-analysis including 278 patients with UCD reported that resective surgery is safe and should be considered 
the gold standard for treatment. Seven retrospective studies enhance this standpoint. Radiotherapy (RT) has been used in six 
studies with controversial results.
Conclusions: We conclude that surgical resection appears to be the most effective treatment for Unicentric Castleman’s Disease 
of the thoracic cavity. Radiotherapy can also achieve clinical response and cure in selected patients.
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Adv Respir Med. 2018; 86: 36–43
Introduction
Castleman’s disease (CD) is a rare non-clonal 
lymph proliferative disorder of unknown etio-
logy, which was first described as a pathologic 
entity in 1954 and later defined by Dr. Benjamin 
Castleman in 1956 [1, 2]. It is a benign tumorous 
process of lymphocyte cell lines, whose multi-
plication leads to excessive expansion of lymph 
nodes. This disorder has also been reported 
using various synonyms, which include giant 
lymph node hyperplasia, lymph node hamarto-
ma, benign giant lymphoma and angiofollicular 
lymph node hyperplasia. Three basic histopa-
thologic subtypes have been described: hyaline 
vascular (HV) (about 70-90% of individuals), 
plasma cell (PC), and mixed variant (MV) [3, 4]. 
All of these pathologic types present clinically 
as lymphadenopathy, with or without constitu-
tional symptoms. There are 2 different clinical 
entities: the unicentric type (UCD) in which 
only one anatomic lymph node affected and the 
multicentric type characterized by generalized 
lymphadenopathy, constitutional symptoms, or-
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ganomegaly and more aggressive clinical course 
with the potential for malignant transformation 
[5–7]. This distinction is important for prognosis 
and determination of the type of therapy. The 
mediastinum is the most common location for 
localized CD, with less common extrathoracic 
sites being the neck, axilla, abdomen, and 
pelvis. Localized type is often asymptomatic at 
presentation and sometimes there are symptoms 
related to local pressure from the mass, like 
cough, chest pain, and dyspnea. Although the 
cause of CD is unknown, several theories have 
been formulated to account for the spectrum of 
associated pathologic and clinical features and 
various immunopathologic processes have been 
suggested [8–10]. The diagnosis of CD should be 
considered only after other more common cau-
ses of lymphadenopathy have been investigated 
and ruled out. The optimal treatment of Castle-
man’s disease is unknown. However, experience 
with this disease has demonstrated subsets of 
patients for whom surgery alone appears to be 
definitive therapy. The surgical treatment is 
variable, ranging from standard thoracotomy to 
minimally invasive video-assisted thoracoscopy. 
Our principle objective is to provide a critical 
analysis of the literature if in patients with 
intrathoracic unicentric Castleman’s disease is 
surgical resection sufficient for achieving cure 
and excellent long-term outcome.
Material and methods 
The systematic review was conducted ac-
cording to the PRISMA guidelines (Preferred 
Reporting Items for Systematic Reviews and 
Meta-Analysis) including articles in English 
language referring to human patients at any age, 
gender and race with localized lesions of Castle-
man’s disease. Studies referring to multicentric 
Castleman’s disease, case reports letters to the 
editors and “Expert” opinion without critical ap-
praisal were excluded from this study. No sample 
size restriction was applied during the screening 
for eligible studies.
The last Bibliographic search was conducted 
in January 16, 2018, and included the following 
electronic databases: Medline (PubMed), the 
Cochrane Database of Systematic Reviews and 
grey literature databases. The following medical 
subject heading terms were used in combination 
with Boolean operators (AND, OR, NOT): Giant 
Lymph Node Hyperplasia, Castleman’s disease, 
unicentric, unifocal, localized, treatment, mana-
gement, multicentric. 
Medline/PubMed
The Medical Subject Headings (MeSH) “Giant 
Lymph Node Hyperplasia” and “Castleman Dise-
ase” were exploded and combined by the Boolean 
operator “OR” with the text word “Castleman”. 
The text word “Castleman” was used to include in 
our search the recently published articles which 
are not MeSH indexed yet. The aforementioned 
search was combined by the Boolean operator 
“AND” with the set “unifocal OR unicentric OR 
localized”. In order to narrow our search, we com-
bined this set with the Boolean operator “AND” 
and the MeSH term “Therapeutics”.
The final search string was the following: 
(unicentric OR unifocal OR localized) AND [(“Ca-
stleman Disease”[Mesh]) OR Castleman)] AND 
(“Therapeutics”[Mesh]).
Cochrane database
Our search was conducted using the text 
words “Castleman disease” and “Giant Lymph 
Node Hyperplasia” returning one relevant case 
report.
Grey Literature
Additionally to the initial search, we scan-
ned the following grey literature databases: The 
Healthcare Management Information Consortium 
(HMIC) database, OpenSIGLE, The National 
Technical Information Service (NTIS) database. 
Applying no restriction upon study type, our 
search was conducted using the text words “Ca-
stleman disease”.
The search protocol was applied by two 
independent reviewers (AS, SM) and all disa-
greements were resolved by consensus with 
a third reviewed (NP). Following the identification 
of all studies retrieved from the initial search, 
both articles’ references lists and relative articles 
were searched in a snowball procedure. No direct 
patients contact took place at any stage of our 
project. Corresponding authors were contacted 
when there was no data for the treatment applied. 
Data from each study was recorded into an Excel 
spread sheet to allow ease of comparison. 
Results and discussion
The initial literature search returned 359 po-
tentially relevant records. Following the removal 
of doubles, application of exclusion/inclusion 
criteria and review of their title and abstract, 23 
reports were retrieved for full-text evaluation. 
Overall, 14 studies were identified for satisfying 
the predetermined search criteria and providing 
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the best available evidence. Each paper was re-
viewed by at least two of the authors. These are 
presented in Table 1. No prospective randomized 
control studies were identified. Ultimately, one 
meta-analysis including 278 patients with UCD 
reported that resective surgery is safe and should 
be considered the gold standard for treatment. 
Seven retrospective studies enhance this stand-
point. Radiotherapy (RT) has been used in six stu-
dies with controversial results. Figure 1 displays 
the flow chart with the process of study selection.
Talat et al. [11] performed a systematic review 
and meta-analysis of 239 articles for a total of 404 
patients with Castleman’s disease between 1954 
and 2009. Of 278 patients with UCD, 249 patients 
underwent respective surgery, 13 had combined 
resective surgery with immunosuppressive the-
rapy and 16 had immunosuppressive therapy 
alone. Ten years’ follow-up revealed 13 disease 
related deaths. The authors found that in patients 
with UCD, surgical excision is safe and should be 
considered the gold standard for treatment.
Ye et al. [12] conducted a retrospective study 
of 52 patients with Castleman’s disease between 
1999 and 2008. 48 patients had UCD and in 22 
cases the lesion was located in the mediastinum. 
All 48 patients underwent complete surgical re-
sections, resulting to a resolution of all symptoms 
and no evidence of disease recurrence during the 
follow-up period (22–115 months). The authors 
attributed that the standard therapy of UCD is 
surgical excision, which has been proven to be 
curative upon complete ‘en-block’ resection.
Luo et al. [13] in their retrospective analysis 
of 48 patients with Castleman’s disease hospitali-
zed between 1992 and 2012, reviewed 16 cases of 
UCD. In this study, all cases had abnormal chest 
CT: in 100% there was present hilar and or me-
diastinal lymphadenopathy, diffuse parenchymal 
lung disease (43.75%), pleural effusion (40.6%), 
mediastinal mass (6.25%) or hilum (3.12%) and 
bronchiolitis obliterans (3.12%). Open thoracic 
surgery was performed in all patients with UCD 
(1 case underwent VATS initially, then converted 
to open thoracic surgery) with perfect survival 
rates. None of the cases were treated with che-
motherapy. Surgery was the preferred treatment 
for intrathoracic UCD masses.
Surgical excision appears to be the ideal 
treatment approach for UCD in five other small 
retrospective studies [14–18]. In total 55 patients 
with UCD were reviewed, all were treated with 
surgery (open thoracic surgery or VATS). Ko et al. 
[15] reported that radical excision of the lesion 
through either an open thoracotomy or VATS can 
produce an equally satisfying outcome with no 
disease recurrence during the follow-up period 
(range, 1 to 16 years; mean, 6.5 years). Both Zhou 
et al. [17] and Kim et al. [18] reported two cases of 
recurrence after surgical removal. For that reason, 
close follow-up is advised from both authors. 
Five retrospective studies [19–23] and one 
case series with review of the literature [24] repor-
ted the use of radiotherapy in the management of 
UCD. Three of these studies [19–21] have shown 
that radiotherapy is the choice of treatment in 
patients who cannot undergo surgery due to un-
resectability. The result was significant reduction 
in tumor size. Keller [22] conducted a retrospec-
tive study of 81 cases with Castleman’s disease 
(74 hyaline-vascular lesions and 7 plasma-cell 
lesions). Although in four patients with hyaline
-vascular lesions radiotherapy was initially admi-
nistered, the mass persisted and ultimately was 
resected. Complete surgical excision was curative 
in the rest of the hyaline-vascular lesion cases 
and in those with plasma-cell lesions. Authors 
concluded that in patients with unresectable UCD 
lesions, radiotherapy will shrink the tumor and 
eventually lead to regression of the symptoms. 
Neuhof et al. [23] reported the outcome in a small 
series of five patients with UCD that were mana-
ged either with surgery (partial excision) followed 
by post-operative RT or with RT alone. Patients 
who had the dual therapy showed no progression 
of the disease during the follow-up. In the 3 pa-
tients who had radiotherapy alone, two showed 
no progression of the disease after radiation and 
one suffered from serious acute and late compli-
cations (dermatitis, paraneoplastic pemphigus 
vulgaris, stenosis of the esophagus, left bronchus, 
and trachea). Accordingly, the authors reported 
that RT can be effective in treating UCD but 
a close follow-up is necessary in order to detect 
possible complications. Parez et al. [24] presented 
83 pediatric patients with Castleman’s disease 
(72 with UCD and 11 with MCD) evaluating the 
clinical features and the treatments’ outcomes. 
Complete excision was performed in 70 patients 
with UCD. Two UCD patients underwent radiation 
therapy. They concluded that complete recovery 
occurs either by surgically resection or local RT.
The appraised systematic review/meta- 
-analysis suggests that resective surgery with 
no further multimodal approach, is the gold 
standard regarding the management of unicen-
tric Castleman’s  disease. However, there are 
some restrictions concerning the location of the 
lesion (e.g. visceral territories). In these cases, 
the operability and matters of technical support 
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Table 1. The characteristics of all included studies
Reference,
study type
(level
of evidence)
Patient group Outcomes Key results Comments
Talat et al. [11]
Review and 
Meta-analysis 
of retrospective 
cohort studies
Systematic 
review of 239 
articles
 of Castle-
man’s disease 
between 1954 
and 2009
n = 404 
(UCD, n = 278; 
MCD, n = 126
Treatment 
modalities and 
outcomes
62/278 of patients with UCD (94.2%) underwent 
resective as opposed to diagnostic surgery
Endoscopic techniques were used in 5  
of 68 patients (7.3%) with
 intrathoracic disease and in 3 of 93 patients 
(3.2%) with intra-abdominal disease
In UCD treatment:
• Resective/diagnostic 262/16 (94.2%)
• Resective Surgery alone (Yes/no 249/29)
• Resective Surgery + immunosuppressive thera-
py (Yes/no 13/265)
• Immunosuppressive therapy alone (Yes/no 
16/262)
• Death due to disease during follow-up up  
to 10 years (Yes/no 13/265)
In patients with UCD, it can 
be concluded that resective 
surgery is safe and should 
be considered the gold 
standard for the treatment
A wedge resection may 
be the first step, but once 
a diagnosis of UCD has 
been established complete 
resection of the lymph 
node and/or its surrounding 
lymph nodes should be 
pursued to achieve surgical 
cure
Ye et al. [12]
Retrospective 
cohort study
Study period: 
1999–2008  
at a single  
institution
n = 52 patients 
(48 with UCD) 
and 4 with 
MCD) 
Clinical efficacy 
of treatment and 
outcomes
22/48 UCD patients (46%) lesion located in the 
mediastinum
All 48 patients with UCD underwent complete sur-
gical resections
No patients with UCD received chemotherapy  
or radiotherapy after surgical resection
No recurrences have been reported after total exci-
sion within the 22–115 months of follow-up period
Standard therapy of UCD 
is surgical excision, which 
has been proven to be 
curative upon complete 
resection and en-bloc
All 48 patients with UCD 
underwent a complete sur-
gical resection and survived 
with excellent prognosis
Luo et al. [13]
Retrospective 
cohort study 
Study period: 
1992 and 2012
n = 48 (16 
cases with UCD 
and 32 cases 
with MCD)
Clinical spectrum 
and treatment of 
intrathoracic Ca-
stleman disease 
All cases had significant abnormalities on their 
chest CT, including obvious lymphadenopathy in 
the hilum and/or mediastinum (100%), diffuse pa-
renchymal lung disease (43.75%), pleural effusion 
(40.6%), mass in the mediastinum (6.25%) or hilum 
(3.12%) and bronchiolitis obliterans (3.12%)
All UCD cases had thoracic surgery for diagnosis 
and treatment 
Open thoracic surgery 16/100%, VATS 1/16.67% 
(1 with UCD was performed VATS initially, then he 
was changed to open thoracic surgery)
None of the cases were treated with chemothera-
py and all of them were alive
Standard therapy of UCD is 
surgical excision
Chen et al. [14]
Retrospective 
study, Single 
center 
Study period:
1994 to 2003
n = 20 
(19 with UCD, 
1 with MCD)
Survival and 
recurrence 
after surgery in 
superficial and 
deep Castleman 
disease
11 patients had superficial disease and 9 had deep 
lesions
5 out of 9 deep lesions were located in the media-
stinum
Surgical outcome after complete resection was 
excellent
No evidence of recurrence (disease free after 
a median follow up of 56 months)
Complete resection of 
unicentric disease certainly 
appeared to be curative to 
all patients 
Ko et al. [15]
Retrospective 
study, Three 
medical faci-
lities
Study period: 
1980–2002
n = 8 (all UCD)
Surgical outco-
mes (open thora-
cotomy, VATS)
Open thoracotomy in 6
Video-assisted thoracoscopic surgery (VATS) in 2
No tumor recurrence during follow-up (range,
 1 to 16 years; mean, 6.5 years)
Radical excision of the 
lesion through open thora-
cotomy or VATS can pro-
duce an equally satisfying 
outcome
Mohanna et al. 
[16]
Retrospective 
study, Two Ho-
spitals
Study period: 
1985–2003 and 
1985–2001
n = 10 
(9 with UCD 
and 1 with MCD)
Characteristics 
of Castleman di-
sease and treat-
ment outcomes
Treatment was complete surgical resection
No evidence of recurrence
The treatment for localized 
forms of CD is complete 
surgical excision
Æ
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Reference,
study type
(level
of evidence)
Patient group Outcomes Key results Comments
Zhou et al. [17]
Retrospective 
study, Single 
center
Study period: 
2003-2008
n = 10 
(8 with UCD 
and 2 with MCD)
Evaluate the 
clinical features, 
diagnosis and 
outcomes of sur-
gical treatment
The primary treatment for patients with UCD was 
complete surgical resection
At the time of writing (June 2011), all 10 patients 
were alive: 9 with no evidence of recurrence or
 exacerbation of CD, and 1 with symptoms
 of CD
UCD is usually of the 
hyaline vascular form and 
complete surgical excision 
of the tumor allows full re-
covery in most cases
Kim et al. [18]
Retrospective 
study, Single 
center
Study period: 
1981–1992
n = 7
Evaluate the 
clinical features, 
diagnosis and 
outcomes of sur-
gical treatment
Lesions located in various sites: lung hilus  
(4 cases), posterior mediastinum (1 case), intrapul-
monary fissure (1 case), and intercostal space  
(1 case)
Surgical removal was done by conventional thora-
cotomy
In 1 patient, recurrence was observed 9 years after 
surgical removal
Surgical resection and close 
follow-up are advised
Bowne et al. 
[19]
Retrospective 
study, Single 
center 
Study period: 
1986–1997
n =16  
(13 with UCD, 
3 with MCD)
Analysis of the 
clinical characte-
ristics, treatment, 
and outcomes
10 patients (77%) with UCD underwent a complete 
surgical resection
3 patients (23%) with unresectable UCD were tre-
ated with partial resection, external beam radiation 
therapy, and observation alone
Of the 10 patients following definitive surgical 
resection, all remain asymptomatic and free of 
disease at last follow-up
The 2 patients treated with partial resection and 
observation only are currently asymptomatic, with 
no further progression of disease, with a follow-up 
of 12 and 76 months, respectively
The patient treated with radiation therapy alone 
demonstrated a minimal decrease in tumor size 
and remains without symptoms
Surgical resection for 
patients with the UCD is 
recommended
Surgical removal of 
a unicentric mass of 
hyaline-vascular or hyaline
-vascular/plasma cell type 
is curative
Partial resection, radiothe-
rapy, or observation alone 
may avoid the need for 
excessively aggressive 
therapy
Chronowski et 
al. [20]
Retrospective 
study, Single 
center 
Study period: 
1988–1999
n = 21  
(12 with UCD 
and 9  
with MCD)
Analysis of treat-
ment outcomes 
after surgery or 
radiotherapy
4 patients with unicentric disease were treated 
with radiotherapy alone: 2 remain alive and symp-
tom free, 2 died of causes unrelated to Castleman 
disease and had no evidence of disease at last 
follow-up
8 patients with unicentric disease were treated 
with complete or partial surgical resection, and all 
are alive and asymptomatic
Mean follow-up time: 51 months (median,  
40 months)
Surgery results in excellent 
rates of cure in patients 
with unicentric Castleman 
disease; radiotherapy can 
also achieve clinical respon-
se and cure in for patients 
not deemed good surgical 
candidates or in patients 
who have undergone in-
complete surgical excision
Uysal et al. 
[21]
Retrospective 
study, Single 
center 
Study period: 
1980–2012
n = 11  
(7 with UCD 
and 4 with MCD)
Analysis of treat-
ment outcomes 
after surgery or 
radiotherapy
6 unicentric patients underwent complete surgical 
excision
1 unicentric patient was managed with incisional 
biopsy
RT is an effective treatment 
option for CD recurrences 
and sole treatment for unre-
sectable CD
Keller et al. [22]
Retrospective 
study
n = 81 (74 
hyaline-vascular 
lesions and 7 
plasma-cell 
lesions)
Clinical spectrum 
and treatment of 
hyaline-vascular 
and plasma-cell 
type of giant 
lymph node hy-
perplasia 
Hyaline-vascular type: 
• complete surgical excision was curative in all 
the patients 
• RT was administered in 4 cases (in all 4 cases, 
the mass persisted and ultimately was resected)
Plasma-cell type:
• complete surgical excision was curative in all 
the patients 
Complete surgical excision 
is the treatment of choice in 
cases of giant lymph node 
hyperplasia
If complete excision is not 
possible, partial excision 
may be useful since regro-
wth of the lesion after this 
procedure is not expected
Radiotherapy has produced 
little shrinkage
Table 1. cont. The characteristics of all included studies
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Reference,
study type
(level
of evidence)
Patient group Outcomes Key results Comments
Neuhof et al. 
[23]
Retrospective 
study, Single 
center
Study period: 
1991–2005
n = 5 (all UCD)
Analyse the 
responses to 
therapy and 
clinical outcomes 
of patients with 
UCD treated with 
RT (alone or after 
surgery) at a sin-
gle institution
2 patients treated with surgery (partial resection) 
and postoperative RT showed no progression of 
disease during follow-up: 1 patient was in comple-
te remission, 1 patient in partial remission
Among the 3 patients treated with RT alone,  
2 patients showed no progression of disease and  
1 showed serious acute and late toxicities (derma-
titis, paraneoplastic pemphigus vulgaris, stenosis 
of the esophagus, left bronchus, and trachea) 
The study shows that uni-
centric Castleman disease 
is successfully treated with 
radiotherapy
 However, for detection 
of possible complications 
as pemphigus vulgaris or 
stenosis of
 the esophagus or trachea 
an accurate follow-up is 
necessary
Parez et al. [24]
Review and 
Case series
Study period: 
1954–1998
n = 83  
(72 with UCD 
and 11  
with MCD)
Evaluate the 
clinical features 
and outcomes of 
treatment in pe-
diatric patients
Localized in the thorax in 33% cases  
(mediastinum: 16, hilum: 7, lung: 1)
Complete excision of the mass was performed in 
all localized cases, except in 2 cases where radia-
tion therapy was used
2 additional cases had spontaneous regression
Complete and permanent recovery occurred when 
the tumor was completely resected. The 2 cases 
with radiation therapy also completely recovered
Complete recovery occurs 
when the localized tumor is 
completely resected or tre-
ated with local radiotherapy
Table 1. cont. The characteristics of all included studies
Records identied through 
database searching
(n = 358)
S
c
re
e
n
in
g
In
c
lu
d
e
d
E
li
g
ib
il
it
y
Id
e
n
ti

c
a
ti
o
n
Additional records identied 
through other sources
(n = 1)
Records after duplicates removed
 
(n = 358)
  
Records screened
 
(n = 358)
  Records excluded
(n = 335)
 
Full — text articles assessed 
for eligibility
 
(n = 23)
  
Full — text articles excluded, 
with reasons
(n = 9)
Studies included in 
qualitative synthesis
 
(n = 14)
  
Studies included in 
quantitative synthesis 
(meta–analysis)
(n = 0)
Figure 1. Flow chart with the process of study selection
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affect the surgical decision making. Outcome of 
surgery is better in peripheral than in visceral 
locations. Authors performed an outcome analysis 
according to which, the only significant predictor 
for fatal outcome is failure to resect the primary 
involved lymph node. Moreover, they point that 
resection with disease free margins, minimizes 
the recurrence rate.
Patients with UCD who underwent surgery 
(had significantly high overall survival (95.3%), 
3-year disease-free survival (89.7%) and 5-year 
disease-free survival (81.2%). In patients who 
failed to be treated by resective surgery there has 
been reported mortality of 17.6% [11]. Regarding 
the alternative choices in the management of 
UCD, radiotherapy is the only well described. 
Radiotherapy can also achieve clinical response 
and cure in patients unsuitable for surgery or in 
patients who have undergone incomplete surgi-
cal excision. However, there have been reported 
possible complications and high recurrence 
rates [19–24].
The authors tried to minimize publication, 
citation, location and outcome reporting bias, by 
independently conducting a systematic review 
in the main scientific databases under the same 
strict protocol. However, the main limitation of 
the current systematic review is the retrospective 
character of the retrieved studies. Several case 
reports and small retrospective studies have 
reported the characteristics and therapeutic 
strategies utilized in patients with UCD, and 
thus the design of appropriate prospective stu-
dies remains puzzling. On the other hand, due 
to the rarity of this disease, it is challenging to 
design a prospective study. The creation of an 
internet-based registry that could include cases 
from several institutions could fulfil the gap in 
high evidence studies which we noted. Moreover, 
another limitation is that only studies in English 
language where included in this review, and thus 
there is possible language bias.
Conclusion
Considering the existing data for the mana-
gement on unifocal Castleman’s disease, we can 
conclude that surgical resection appears to be the 
most effective treatment for resectable lesions in 
any organ domain. Although radiotherapy rema-
ins a  therapeutic option in patients unsuitable 
for surgery, we would recommend caution in its 
application and accurate follow-up, as there have 
been reported possible complications and recur-
rence of the disease. Future research should focus 
on less invasive interventions, including molecu-
lar therapeutics using effective targeted agents 
that could target selectively Castleman’s disease 
lesions.
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